Amgen posts higher biosimilar sales, ends neuroscience program
(Reuters) – Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall…
Targeted Amgen drug has low response rate in colon cancer in study
(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest…
Patent court to review Alexion’s Soliris patents on Amgen challenge
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. FILE PHOTO: An…